Faeth Therapeutics, Inc. (SNSE) Form 8-K — Oct 27, 2026
Faeth Therapeutics' board expanded from six to seven directors and appointed Adam Schayowitz, Ph.D., as a Class III director effective October 23, 2026. Dr. Schayowitz brings deep oncology development experience, currently serving as EVP and Head of R&D at Zymeworks after senior roles at Pfizer Oncology, Tesaro, and Algeta, including development leadership for Zejula. He received an initial option grant for 25,000 shares under the 2026 Equity Incentive Plan, vesting monthly through the third anniversary and fully upon a change in control.
Key figures
- Board size after
- 7
- Board size before
- 6
- Initial option grant shares
- 25000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.